157 related articles for article (PubMed ID: 15678015)
1. Azacitine (vidaza) for myelodysplastic syndrome.
Med Lett Drugs Ther; 2005 Jan; 47(1201):11. PubMed ID: 15678015
[TBL] [Abstract][Full Text] [Related]
2. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes.
Kaminskas E; Farrell A; Abraham S; Baird A; Hsieh LS; Lee SL; Leighton JK; Patel H; Rahman A; Sridhara R; Wang YC; Pazdur R;
Clin Cancer Res; 2005 May; 11(10):3604-8. PubMed ID: 15897554
[TBL] [Abstract][Full Text] [Related]
3. FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension.
Kaminskas E; Farrell AT; Wang YC; Sridhara R; Pazdur R
Oncologist; 2005 Mar; 10(3):176-82. PubMed ID: 15793220
[TBL] [Abstract][Full Text] [Related]
4. Review of azacitidine trials in Intermediate-2-and High-risk myelodysplastic syndromes.
Fenaux P; Ades L
Leuk Res; 2009 Dec; 33 Suppl 2():S7-11. PubMed ID: 20004796
[TBL] [Abstract][Full Text] [Related]
5. Advances in myelodysplastic syndrome: nursing implications of azacitidine.
Demakos EP; Linebaugh JA
Clin J Oncol Nurs; 2005 Aug; 9(4):417-23. PubMed ID: 16117208
[TBL] [Abstract][Full Text] [Related]
6. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.
Silverman LR; McKenzie DR; Peterson BL; Holland JF; Backstrom JT; Beach CL; Larson RA;
J Clin Oncol; 2006 Aug; 24(24):3895-903. PubMed ID: 16921040
[TBL] [Abstract][Full Text] [Related]
7. Azacitidine: activity and efficacy as an epigenetic treatment of myelodysplastic syndromes.
Santini V
Expert Rev Hematol; 2009 Apr; 2(2):121-7. PubMed ID: 21083445
[TBL] [Abstract][Full Text] [Related]
8. [Pharmacological profiles and clinical roles of 5-azacitidine (Vidaza(®) for injection 100 mg) for the treatment of myelodysplastic syndrome (MDS)].
Takahashi Y; Kimura S; Okano M
Nihon Yakurigaku Zasshi; 2012 Nov; 140(5):235-43. PubMed ID: 23138323
[No Abstract] [Full Text] [Related]
9. Azacitidine. Poor-prognosis myelodysplasia: promising, but more data needed.
Prescrire Int; 2011 Feb; 20(113):40. PubMed ID: 21488589
[TBL] [Abstract][Full Text] [Related]
10. Response to 5-azacytidine in a patient with relapsed Hodgkin Lymphoma and a therapy-related myelodysplastic syndrome.
D'Alò F; Leone G; Hohaus S; Teofili L; Bozzoli V; Tisi MC; Rufini V; Calcagni ML; Voso MT
Br J Haematol; 2011 Jul; 154(1):141-3. PubMed ID: 21332703
[No Abstract] [Full Text] [Related]
11. Cytogenetic response is not a prerequisite for clinical response in patients with myelodysplastic syndromes treated with azacitidine.
Gangatharan SA; Carney DA; Campbell LJ; Prince HM; Kenealy MK; Seymour JF
Eur J Haematol; 2011 Aug; 87(2):186-8. PubMed ID: 21623918
[No Abstract] [Full Text] [Related]
12. Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinion.
Fenaux P; Bowen D; Gattermann N; Hellström-Lindberg E; Hofmann WK; Pfeilstöcker M; Sanz G; Santini V
Leuk Res; 2010 Nov; 34(11):1410-6. PubMed ID: 20609474
[TBL] [Abstract][Full Text] [Related]
13. Is there an association between 5-azacitidine and ototoxicity?
Malik A; Misbah S; Spaccavento C; Yudelman I
J Clin Pharmacol; 2010 Sep; 50(9):1056-7. PubMed ID: 20234015
[No Abstract] [Full Text] [Related]
14. 5'-Azacitidine for therapy-related myelodysplastic syndromes after non-Hodgkin lymphoma treatment.
Breccia M; Salaroli A; Loglisci G; Martelli M; D'Elia GM; Nanni M; Mauro FR; Alimena G
Leuk Res; 2011 Oct; 35(10):1409-11. PubMed ID: 21680017
[TBL] [Abstract][Full Text] [Related]
15. 5'-azacitidine in myelodysplastic syndromes with inversion of chromosome 3.
Breccia M; Cannella L; Santopietro M; Loglisci G; Federico V; Salaroli A; Nanni M; Mancini M; Alimena G
Leukemia; 2011 Apr; 25(4):736-7. PubMed ID: 21293489
[No Abstract] [Full Text] [Related]
16. Azacitidine.
Issa JP; Kantarjian H
Nat Rev Drug Discov; 2005 May; Suppl():S6-7. PubMed ID: 15962522
[TBL] [Abstract][Full Text] [Related]
17. Azacitidine.
Issa JP; Kantarjian HM; Kirkpatrick P
Nat Rev Drug Discov; 2005 Apr; 4(4):275-6. PubMed ID: 15861567
[No Abstract] [Full Text] [Related]
18. Real-life experience with azacitidine in myelodysplastic syndromes according to IPSS cytogenetic profile.
Breccia M; Voso MT; Maurillo L; Niscola P; Fianchi L; Aloe Spiriti MA; Buccisano F; Latagliata R; Pelliccia S; Fenu S; Tendas A; Alimena G
Am J Hematol; 2014 May; 89(5):565. PubMed ID: 24458879
[No Abstract] [Full Text] [Related]
19. [Cost-effectiveness analysis of azacitidine for myelodysplastic syndromes in Japan].
Tomonaga M; Kamae I
Rinsho Ketsueki; 2012 Mar; 53(3):310-7. PubMed ID: 22499047
[TBL] [Abstract][Full Text] [Related]
20. Fas expression at diagnosis as a biomarker of azacitidine activity in high-risk MDS and secondary AML.
Ettou S; Audureau E; Humbrecht C; Benet B; Jammes H; Clozel T; Bardet V; Lacombe C; Dreyfus F; Mayeux P; Solary E; Fontenay M
Leukemia; 2012 Oct; 26(10):2297-9. PubMed ID: 22743624
[No Abstract] [Full Text] [Related]
[Next] [New Search]